Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL lessened its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 50.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,342 shares of the biotechnology company's stock after selling 20,531 shares during the quarter. Tudor Investment Corp ET AL's holdings in Veracyte were worth $806,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Jones Financial Companies Lllp raised its stake in shares of Veracyte by 49.7% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 237 shares during the period. Arizona State Retirement System raised its stake in shares of Veracyte by 1.2% in the 4th quarter. Arizona State Retirement System now owns 22,276 shares of the biotechnology company's stock valued at $882,000 after acquiring an additional 264 shares during the period. Synovus Financial Corp raised its stake in shares of Veracyte by 1.2% in the 4th quarter. Synovus Financial Corp now owns 23,132 shares of the biotechnology company's stock valued at $916,000 after acquiring an additional 267 shares during the period. HighTower Advisors LLC raised its stake in shares of Veracyte by 1.9% in the 4th quarter. HighTower Advisors LLC now owns 16,630 shares of the biotechnology company's stock valued at $659,000 after acquiring an additional 305 shares during the period. Finally, Principal Securities Inc. raised its stake in shares of Veracyte by 34.1% in the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 485 shares during the period.

Veracyte Price Performance

Shares of VCYT stock traded up $0.79 during trading on Monday, reaching $30.50. The company's stock had a trading volume of 448,094 shares, compared to its average volume of 883,183. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of -203.26 and a beta of 2.14. The stock's 50-day moving average price is $31.05 and its 200 day moving average price is $37.15. Veracyte, Inc. has a 1-year low of $19.73 and a 1-year high of $47.32.

Veracyte (NASDAQ:VCYT - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The company had revenue of $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. During the same quarter in the previous year, the business posted ($0.39) EPS. On average, sell-side analysts anticipate that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on VCYT. Stephens reissued an "overweight" rating and issued a $45.00 price target on shares of Veracyte in a research note on Wednesday, March 26th. Craig Hallum began coverage on shares of Veracyte in a research note on Thursday, March 20th. They issued a "buy" rating and a $45.00 price target on the stock. UBS Group reduced their price target on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday. Needham & Company LLC dropped their price objective on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a report on Thursday. Finally, StockNews.com cut shares of Veracyte from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.90.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.